Boardroom Alpha
S-1 primary document
CYAB · Registration Statement (Form S-1) · Filed July 31, 2026

Cyabra IncS-1 exhibit

ea029930301ex-fee.htm
Filing Fee Exhibit

Ex-Filing Fees

CALCULATION OF FILING FEE TABLES

S-1

CYABRA, INC.

Table 1: Newly Registered and Carry Forward Securities

                                           
Line Item Type   Security Type   Security Class Title   Notes   Fee Calculation
Rule
  Amount Registered   Proposed Maximum Offering
Price Per Unit
  Maximum Aggregate Offering Price   Fee Rate   Amount of Registration Fee
                                           
Newly Registered Securities
Fees to be Paid   Equity   Common Stock, par value $0.0001 per share   (1)   Other   150,621,827   $ 0.2750   $ 41,421,002.43   0.0001381   $ 5,720.24
                                           
Total Offering Amounts:   $ 41,421,002.43         5,720.24
Total Fees Previously Paid:               0.00
Total Fee Offsets:               0.00
Net Fee Due:             $ 5,720.24

__________________________________________
Offering Note(s)

(1) Includes up to an aggregate of 150,621,827 shares of Common Stock that may be offered and sold from time to time by the selling shareholders, consisting of: (i) 1,175,090 shares of Common Stock; (ii) 12,643,680 shares of Common Stock issuable upon the exercise of pre-funded warrants; (iii) 13,818,770 shares of Common Stock issuable upon the exercise of Series A warrants; (iv) 13,818,770 shares of Common Stock issuable upon the exercise of Series B warrants; (v) 35,648,276 shares of Common Stock issuable upon the conversion of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (or upon the exercise of pre-funded warrants that may be issued in lieu thereof), (vi) 24,505,747 shares of Common Stock (or shares of Common Stock issuable upon the exercise of pre-funded warrants that may be issued in lieu thereof), 24,505,747 shares of Common Stock issuable upon the exercise of Series A Warrants and 24,505,747 shares of Common Stock issuable upon the exercise of Series B Warrants, in each case issuable pursuant to the exchange of our Series C Convertible Preferred Stock.

Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers an indeterminate number of additional shares of Common Stock that may become issuable as a result of stock splits, stock dividends, recapitalizations or similar transactions.

Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act, based on the average of the high ($0.290) and low ($0.260) sale prices of the Registrant’s Common Stock as reported on The Nasdaq Global Market on July 24, 2026, which was $0.275 per share.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer